TY  - JOUR
AU  - Schaffrath, Anja
AU  - Schleyken, Sophia
AU  - Seger, Aline
AU  - Jergas, Hannah
AU  - Özdüzenciler, Pelin
AU  - Pils, Marlene
AU  - Blömeke, Lara
AU  - Cousin, Anneliese
AU  - Willbold, Johannes
AU  - Bujnicki, Tuyen
AU  - Bannach, Oliver
AU  - Fink, Gereon R.
AU  - Willbold, Dieter
AU  - Sommerauer, Michael
AU  - Barbe, Michael T.
AU  - Tamgüney, Gültekin
TI  - Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool
JO  - npj Parkinson's Disease
VL  - 9
IS  - 1
SN  - 2373-8057
CY  - London [u.a.]
PB  - Nature Publ. Group
M1  - FZJ-2023-01236
SP  - 14
PY  - 2023
AB  - Misfolded and aggregated α-synuclein is a neuropathological hallmark of Parkinson’s disease (PD). Thus, α-synuclein aggregates are regarded as a biomarker for the development of diagnostic assays. Quantification of α-synuclein aggregates in body fluids is challenging, and requires highly sensitive and specific assays. Recent studies suggest that α-synuclein aggregates may be shed into stool. We used surface-based fluorescence intensity distribution analysis (sFIDA) to detect and quantify single particles of α-synuclein aggregates in stool of 94 PD patients, 72 isolated rapid eye movement sleep behavior disorder (iRBD) patients, and 51 healthy controls. We measured significantly elevated concentrations of α-synuclein aggregates in stool of iRBD patients versus those of controls (p = 0.024) or PD patients (p < 0.001). Our results show that α-synuclein aggregates are excreted in stool and can be measured using the sFIDA assay, which could support the diagnosis of prodromal synucleinopathies.
LB  - PUB:(DE-HGF)16
C6  - 36732520
UR  - <Go to ISI:>//WOS:001002245600001
DO  - DOI:10.1038/s41531-023-00458-4
UR  - https://juser.fz-juelich.de/record/1002038
ER  -